The estimated Net Worth of Ying Du is at least $61.4 Milione dollars as of 28 June 2024. Dr Du owns over 17,970 units of Zai Lab stock worth over $23,488,069 and over the last 4 years he sold ZLAB stock worth over $36,516,256. In addition, he makes $1,376,036 as Founder e Chairperson & CEO at Zai Lab.
Dr has made over 15 trades of the Zai Lab stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 17,970 units of ZLAB stock worth $387,613 on 28 June 2024.
The largest trade he's ever made was exercising 300,000 units of Zai Lab stock on 3 March 2023 worth over $6,471,000. On average, Dr trades about 51,974 units every 51 days since 2021. As of 28 June 2024 he still owns at least 1,088,923 units of Zai Lab stock.
You can see the complete history of Dr Du stock trades at the bottom of the page.
Dr. Ying Du is the Founder, Chairperson & CEO at Zai Lab.
As the Founder e Chairperson & CEO of Zai Lab, the total compensation of Dr Du at Zai Lab is $1,376,036. There are no executives at Zai Lab getting paid more.
Dr Du is 55, he's been the Founder e Chairperson & CEO of Zai Lab since . There are 11 older and 9 younger executives at Zai Lab. The oldest executive at Zai Lab Limited is John Diekman, 77, who is the Independent Director.
Ying's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Zai Lab have traded over $44,173,112 worth of Zai Lab stock and bought 19,000 units worth $666,380 . The most active insiders traders include Ying Du, William Lis e John D Diekman. On average, Zai Lab executives and independent directors trade stock every 14 days with the average trade being worth of $432,845. The most recent stock trade was executed by Richard Gaynor on 3 September 2024, trading 2,500 units of ZLAB stock currently worth $48,750.
zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve
Zai Lab executives and other stock owners filed with the SEC include: